RecruitingNCT06442423
Open-label psilocybin for mental health symptoms affecting daily life
About this title
Read the official source — NCT06442423This study evaluates the safety of Psilocybin for people with anxiety.
Medication studyAges 18+United StatesDepression
Understand this study
What is this study about?
This study evaluates the safety of Psilocybin for people with anxiety.
Who could participate?
Listed age limits: from 18 years.
What will I do during this study?
You receive one oral dose of psilocybin (25 mg), with support before, during and after the dosing session. Follow-up assessments take place one, four and six weeks after dosing. If you agree to optional longer follow-up, further assessments take place at three, six and twelve months.
- Listed locations
- New HavenSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: October 17, 2024
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 50
- Sponsor
- Yale University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT06442423
- Official title
Show the full official title
Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept Study
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
New Haven
Interested in joining this study?
Questions about this study
What is this study about?
This study evaluates the safety of Psilocybin for people with anxiety.
Who is behind this study?
The study sponsor is Yale University, a university.
Does this study involve medication?
Yes. The study involves medication, including Psilocybin.
Who can participate?
Listed age limits: from 18 years.
Is this study still recruiting?
The registry lists this study as recruiting.
